Study Summary
Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell malignancy including lymphoma or leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Autologous CD19-targeting CAR T cellsBIOLOGICAL
Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| No.2 Hospital of Hebei Medical University | Shijiazhuang | Hebei | China |